PROTOCOLS
FOR THE TREATMENT
OF
HEMOPHILIA
AND
VON WILLEBRAND DISEASE
(Revised April 2021)

Hemophilia of Georgia
8607 Roberts Dr #150, Sandy Springs,
Georgia 30350
For 24-hour assistance in the management of problems related to hemophilia call:

Physician’s Hemophilia HOTLINE
1-888-549-6493

Hemophilia of Georgia
9 a.m.-5 p.m. Weekdays
(770) 518-8272
1-800-866-HEMO
FAX: (770) 518-3310

NOTE: If you know the hemophilia treatment center with which the patient is affiliated, please contact that center directly. The names, addresses, and phone numbers of the treatment centers in Georgia can be found on pages 2 and 3 of these protocols.
# TABLE OF CONTENTS

## INTRODUCTION

i

## I. HEMOPHILIA AND ITS DIAGNOSIS

1

## II. TREATMENT FOR BLEEDING EPISODES

(Georgia Hemophilia Treatment Centers)

2

A. BASIC PRINCIPLES OF TREATMENT

4

B. TREATMENT OF HEMOPHILIA A

5

1. Factor VIII

5

2. Non-Factor Products

6

3. Cryoprecipitate

9

4. DDAVP

9

5. Antifibrinolytic Agents

10

C. TREATMENT OF HEMOPHILIA B

10

1. Factor IX

10

2. Fresh Frozen Plasma

12

3. Antifibrinolytic Agents

12

D. SPECIFIC HEMORRHAGES

12

1. Joint Hemorrhage

12

2. Muscle Hemorrhage

13

3. Iliopsoas Hemorrhage

13

4. Central Nervous System Hemorrhage/Head Trauma

14

5. Throat and Neck Hemorrhage and Severe Tonsillitis

14

6. Acute Gastrointestinal Hemorrhage

14

7. Acute Abdomen Hemorrhage

15

8. Ophthalmic Trauma or Hemorrhage

15

9. Renal Hemorrhage

15

10. Oral Hemorrhage

16

11. Epistaxis

16

12. Soft Tissue Hemorrhage

17

13. Lacerations and Abrasions

17

E. VON WILLEBRAND DISEASE

17

## III. OTHER MANAGEMENT ISSUES

19

A. DENTAL

19

B. SURGERY

20

C. INVASIVE PROCEDURES

20

D. IMMUNIZATIONS

20

E. SPORTS AND HEMOPHILIA

21

## IV. COMPLICATIONS OF HEMOPHILIA

22

A. FACTOR INHIBITORS

22

B. SYNOVITIS

22

C. HIV ISSUES

22

D. HEPATITIS C

23

E. ALLERGIC REACTIONS TO FACTOR PRODUCTS

24

Chart — Desired Factor Level and Dosage

25

Appendix — Common Preparations Containing Aspirin

26
INTRODUCTION

Hemophilia of Georgia and the hemophilia treatment centers of Georgia have combined resources and expertise to develop guidelines for physicians who treat patients with hemophilia.

These protocols are meant to assist in providing quality standards of care for the management of hemophilia. They are not intended to replace regular evaluation and treatment by the hemophilia treatment center. It is hoped that communication between the patient’s private physician and the hemophilia center will be enhanced by the existence of these guidelines.

These therapeutic approaches are based on the experiences of the advisors as well as protocols established by other hemophilia centers in the United States. Any treatment must be designed according to the needs of the individual and the resources available.

Hemophilia of Georgia would like to express our sincere appreciation to the Medical Advisory Committee for their input and expertise in preparing this revision of the Protocols for the Treatment of Hemophilia and von Willebrand Disease.
PROTOCOLS FOR THE TREATMENT OF HEMOPHILIA AND VON WILLEBRAND DISEASE

I. HEMOPHILIA AND ITS DIAGNOSIS

Hemophilia A and B are inherited X-linked disorders that are due to deficiencies of clotting factors VIII and IX, respectively. The frequency of factor VIII deficiency is thought to be approximately 1 per 5,000-10,000 male births; for factor IX deficiency it is approximately 1 per 30,000-50,000 male births.

CLASSIFICATION OF PERSONS WITH EITHER HEMOPHILIA A OR HEMOPHILIA B*

<table>
<thead>
<tr>
<th>Severe Hemophilia</th>
<th>Moderate Hemophilia</th>
<th>Mild Hemophilia</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1% factor level</td>
<td>1-5% factor level</td>
<td>6-49% factor level</td>
</tr>
</tbody>
</table>

CLINICAL FEATURES OF PERSONS WITH EITHER HEMOPHILIA A OR HEMOPHILIA B

<table>
<thead>
<tr>
<th>Severe Hemophilia</th>
<th>Moderate Hemophilia</th>
<th>Mild Hemophilia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spontaneous bleeding characteristic</td>
<td>Can bleed with slight injury</td>
<td>Bleeding typically only with severe injury, surgery, invasive procedures</td>
</tr>
<tr>
<td>May bleed 1 to 2 times per week</td>
<td>May bleed 1 time per month</td>
<td>May never have a bleeding problem</td>
</tr>
<tr>
<td>Characterized by joint bleeding (hemarthrosis)</td>
<td>May have joint bleeding</td>
<td>Rarely has joint bleeding</td>
</tr>
</tbody>
</table>

*Normal factor levels are from 50-150%.

Early carrier detection is based on pedigree and DNA analysis. The maternal DNA-based diagnosis is the most accurate but is not informative in all patients. Since factor VIII and IX levels can vary in carriers of hemophilia, factor levels cannot be used to determine carrier status, though they are useful to determine the carrier’s own risk of bleeding with bleeding potentially occurring in those carriers with levels up to 60%.

Prenatal diagnosis is possible by performing a chorionic villous biopsy at 9-11 weeks or an amniocentesis at 12-15 weeks gestation and extracting the DNA from fetal cells for DNA-based diagnosis. For further information regarding availability of testing resources, contact Hemophilia of Georgia or a hemophilia treatment center.

Postpartum diagnosis of hemophilia A relies on the ability to detect low factor VIII coagulant activity in a
suspected newborn on cord blood (preferred) or a peripheral venous blood sample. The level determined from the cord blood may not reflect the exact severity and thus a subsequent FVIII level in the infant will be needed to ensure the severity unless the family severity history is known. The diagnosis of mild hemophilia B or factor IX deficiency is more difficult because the newborn normally has low levels of factor IX coagulant activity (a vitamin K dependent factor). Low levels of factor IX may exist for up to six months in a child who does not have hemophilia. Administration of vitamin K after delivery is acceptable and encouraged in newborns with hemophilia A or B without any factor replacement or antifibrinolytic agents. Arterial, jugular, femoral and antecubital punctures as well as circumcision or other invasive procedures are contraindicated until a diagnosis is obtained and the patient is treated beforehand to achieve an adequate factor level.

**Suggested Technique for Collection of Cord Blood by Obstetricians to Avoid Venipuncture of Newborn (for Factor VIII Assay)**

Immediately after delivery, place clamps in order A through D. Cut the cord as shown and obtain blood from freed section.

**II. TREATMENT FOR BLEEDING EPISODES**

For further recommendations, contact any of the hemophilia treatment centers in Georgia:

**Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory**

(1) Children's Healthcare of Atlanta at Egleston
Aflac Cancer and Blood Disorders Center
Department of Pediatric Hematology and Oncology
1405 Clifton Rd NE, 4th floor
Atlanta, Georgia 30322

(404) 785-1200
Physicians:
Robert Sidonio, M.D., MSc (Pediatrics)
Shannon Meeks, M.D. (Pediatrics)
Carolyn Bennett, M.D., MSc (Pediatrics)
Glaivy Batsuli, M.D. (Pediatrics)
Gary Woods, M.D., (Pediatrics)
Karen Zimowski, M.D. (Pediatrics)
Megan Brown, M.D. (Pediatrics)
Michael White, M.D. (Pediatrics)
Kelly Tickle, NP (Pediatrics)

(2) Emory Clinic Midtown
Department of Hematology and Medical Oncology
550 Peachtree St NE, Medical Office Tower (MOT), 10th floor – Suite 1090
Atlanta, Georgia 30308

Physicians:
Christine Kempton, M.D., MSc (Director)
Maria Ribeiro, M.D. (Adults)
Sidney Stein, M.D. (Adults)
Ana Antun, M.D. (Adults)
Duc “Bobby” Tran, M.D., MSc (Adults)
Lorraine Cafuir, M.D. (Adults)
Anthony DeBalsi, NP (Adults)

The Children’s Hospital of Savannah at Memorial University Medical Center

The Children’s Hospital of Savannah at Memorial University Medical Center
Department of Hematology/Oncology
4750 Waters Avenue, Suite 103
P.O. Box 23089
Savannah, Georgia 31404

Physician: Evangeline Brown, M.D.

Augusta University Comprehensive Hemophilia Program

Augusta University Health System
Department of Adult Hematology and Oncology
1447 Harper St
Augusta, Georgia 30912

Physician: Abdullah Kutlar, M.D.

Augusta University Health System
Department of Pediatric Hematology and Oncology
1447 Harper St
Augusta, Georgia 30912
Physician: Afshin Ameri, M.D.

Hemophilia of Georgia is involved in the coordination and support of these centers. For further information, call (770) 518-8272.

A. Basic Principles of Treatment

1. Treat bleeds early with factor replacement therapy, i.e., within 2 hours of the onset of symptoms. Do not wait for appearance of physical signs.
   (a) Treat a suspected intracranial hemorrhage immediately.
   (b) Most patients, even young children, can recognize joint hemorrhage early in its course. Early recognition and treatment will limit soft tissue damage. In addition, less factor is ultimately needed.
   (c) IF IN DOUBT, TREAT. If a person with hemophilia has sustained an injury or if he/she thinks they may be bleeding, in most cases treat first and perform diagnostic tests once treatment is completed.

2. Treat veins with care. For people with hemophilia, veins are their lifeline.
   (a) 23- or 25-gauge butterfly needles are recommended.
   (b) Never cut-down, except in a dire emergency; a cut-down destroys veins.
   (c) After venipuncture, apply pressure with one or two fingers for three to five minutes.

3. Avoid products that cause platelet dysfunction, especially those containing aspirin. (See Appendix, page 25.) Non-steroidal, anti-inflammatory agents such as ibuprofen should be avoided also. We recommend acetaminophen with or without codeine for pain control.

4. Home therapy with clotting factor is usually begun when a child is one to five years old. The benefits include reduced risk of life-threatening bleeding, short-term and long-term joint complications of hemophilia. Children should be encouraged to participate in their own infusions at an early age. Many hospitals allow patients to bring their own factor for infusion in the emergency room if sent home or prior to outpatient surgery and inpatient if the home product is not available on the hospital formulary.

5. The concept of comprehensive care at a hemophilia treatment center is a state-of-the-art approach to hemophilia treatment. In this setting, the patient is evaluated by a multi-disciplinary team that usually consists of a hematologist, nurse coordinator, social worker and physical therapist and may also consist of an orthopedist, dietician, infectious disease specialist, hepatologist, dentist and dental hygienist, occupational therapist, vocational rehabilitationist, psychologist and genetic counselor. This team devises a coordinated care plan for the patient. A local physician may participate by providing close follow-up in between visits to the hemophilia treatment center.
Communication between the patient’s local physician and the hemophilia treatment center is essential for optimal management.

B. Options Available for the Treatment of a Person with Factor VIII Deficiency (Hemophilia A)

1. Factor VIII

Commercially prepared, lyophilized factor VIII is distributed under a variety of brand names. Since the mid-1980s, new products have been introduced which have undergone viral attenuation. These products fall into four categories: (1) recombinant standard half-life (SHL) products, which include Kogenate FS, Advate, Recombinate, Xyntha, NovoEight, Kovaltry, Afstyla, and Nuwiq; (2) recombinant extended half-life (EHL) products which include Eloctate, Adynovate, Jivi and Esperoct; (3) monoclonal antibody purified plasma-derived products, which include Hemofil-M; (4) intermediate and “high-purity” plasma-derived factor VIII products that contain von Willebrand factor, which include Koate-DVI, Humate-P, Wilate, and Alphanate (all of which have been used to treat von Willebrand Disease, although only Humate P, Wilate and Alphanate are currently licensed for use in Von Willebrand disease). Consult the product package insert for specific instructions. All of these products have undergone viral attenuation. Hemophilia of Georgia does not endorse one particular brand.

There may be specific product recommendations for patients with complications such as inhibitors or HIV infection. Novoseven (recombinant activated factor VIIa) is licensed for the treatment of bleeding in patients with inhibitors to factor VIII or factor IX. The standard dose is 90 mcg/kg given every 4-6 hours until hemostasis is achieved or until treatment is thought to be effective. FEIBA (Factor VIII Inhibitor Bypassing Agent) is also utilized for bleeding in patients with inhibitors to factor VIII only. The standard dose is 50-100 units/kg given every 12-24 hours and total daily dosing should not exceed 200 units/kg due to a potential risk of thrombosis. Consult a hemophilia treatment center at the initiation of therapy if the patient has a problem more complicated than a simple bleed. Consultation with a hematologist is important when FEIBA is used concomitantly with non-factor product emicizumab (Hemlibra) (see pages 6-7).

(a) These products are available for home therapy through Hemophilia of Georgia. Products and are shipped directly to the home. Social workers are available to help Georgia residents explore insurance options.

(b) Vials are available in dosages ranging between approximately 250-4000 units each.

(c) For patients without a factor VIII inhibitor, each factor VIII unit per kilogram of body weight infused intravenously will raise the plasma factor VIII level approximately 2%. The half-life of SHL products is approximately 8-12 hours. The EHL products have half-lives of approximately 12-19 hours, however the half-life may vary with age and typically the half-life extension is minimal in children under the age of 6. The presence of a factor VIII inhibitor may decrease both factor VIII recovery and half-life of SHL and EHL products.

The formula for calculating the dosage for factor VIII is taking the patient’s weight in kilograms, multiplying by the factor level desired, and then dividing by the recovery level (typically 2 IU/dl per IU/kg), which will indicate the number of factor units.
required.

Formula: \[
\text{[Target Factor Level (IU/dl) – Baseline Factor Level (IU/dl)] \times \text{wt in kg}}
\text{Factor Recovery (IU/dl per IU/kg)}
\]

- The target minus the baseline factor VIII level is equal to the desired change in factor level.

Example: For a 45 kg boy with severe hemophilia A (factor VIII <1%) who has a joint bleed for which the desired change in factor level is 40%, the following equation is used:

\[
40 \times 45 \text{ kg} = 900 \text{ units of factor VIII}
\]

Refer to the chart on page 25 for suggested factor level and dosage based on type of hemorrhage.

(d) Factor VIII should be infused by slow IV push. Consult the product insert guide for specific instructions.

(e) Do not waste the content of a prescribed vial. Always give the entire content of each vial of factor VIII even if that exceeds the calculated dosage. Factor is expensive and should not be wasted.

(f) In patients where the factor VIII inhibitor status is unknown or is in question, determination of factor recovery 15-30 minutes after completion of the infusion and supplemented by levels 4-8 hours later by measuring factor VIII levels may be advisable.

(g) In the setting of a limb or life-threatening bleed or major surgery, continuous infusion of factor VIII could be considered when supervised by an experienced hematologist. A 50 IU/kg bolus followed by 3–5 IU/kg per hour of factor VIII will provide a factor VIII level of approximately 100% in a patient with severe hemophilia A without an inhibitor. A patient with severe hemophilia A with an inhibitor that is able to treat with a factor VIII product or a patient with severe hemophilia A with more rapid clearance of factor VIII may require higher rates for their continuous infusions starting at 6-8 IU/kg per hour after the bolus. Initially factor levels should be monitored every 8-12 hours, then monitored daily at minimum once stable.

Factor VIII products are stable in IV solutions for at least 12 hours at room temperature. Therefore, 8–12-hour bags of factor VIII mixed with normal saline for continuous infusion may be prepared by the pharmacy under a biosafety hood and administered without concern for proteolytic inactivation, degradation, or bacterial contamination.

2. **Non-Factor Products**

In November 2017, the FDA approved the first non-factor therapy for patients with hemophilia A and inhibitors called Hemlibra, formerly known as emicizumab-kxwh or ACE910. This medication is a recombinant, humanized, bispecific immunoglobulin G4
(IgG4) monoclonal antibody that mimics the cofactor function of activated factor VIII (factor VIIIa) by bridging activated factor IX (factor IXa) and factor X. In October 2018, FDA approval for Hemlibra was expanded to patients with hemophilia A without factor VIII inhibitors. Hemlibra is now FDA approved for routine prophylaxis to prevent and reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (factor VIII deficiency) with or without factor VIII inhibitors. This medication should only be prescribed and monitored under the supervision of a provider at a hemophilia treatment center due to the higher risk of thrombosis and thrombotic microangiopathy in certain clinical situations.

(a) Dosing and Administration

Hemlibra is administered as a subcutaneous injection at a loading dose of 3 mg/kg once weekly for the first 4 weeks. Following the loading doses, maintenance dosing of Hemlibra is administered at (1) 1.5 mg/kg once every week, (2) 3 mg/kg once every 2 weeks, or (3) 6 mg/kg once every 4 weeks. It is available in 4 dosage forms as single dose vials including a 30 mg/mL vial, 60 mg/0.4 mL vial, 105 mg/0.7 mL vial, and a 150 mg/mL vial. Doses less than or equal to 1 mL should be administered with a 1 mL syringe; doses between 1-2 mL can be administered with a 2 mL or 3 mL syringe. Doses greater 2 mL require more than 1 injection. Subcutaneous injections can be administered at the upper arm, the thigh, or the abdomen (similar to insulin injections used in individuals with diabetes). The half-life of Hemlibra is approximately 28 days and can remain in the plasma for up to 6 months after discontinuation of the medication.

(b) Potential Side Effects

The most common side effects of Hemlibra are local injection site reactions (i.e. irritation, rash), headache, nausea and arthralgias. In rare cases, serious and potentially life-threatening complications of thromboembolism and thrombotic microangiopathy can occur (see below).

(c) Thrombotic Microangiopathy

Thrombotic microangiopathy (TMA) is a condition in which individuals may develop blood clots in the small vessels within the body including the kidneys and brain. They may present with nausea or vomiting, abdominal pain, back pain, confusion, weakness, swelling of the extremities, jaundice, or decreased urination. Laboratory findings may reveal evidence of thrombocytopenia, acute kidney injury, or microangiopathic hemolytic anemia. The complication of TMA and thrombosis has occurred in cases where individuals received activated prothrombin complex concentrate (aPCC) FEIBA, particularly at doses >100 units/kg for >24 hours, while on Hemlibra. No cases have been observed with Novoseven.

If there is any concern for TMA, the patients should seek immediate medical care. At the medical facility, laboratory studies should be performed to evaluate for TMA including (1) a complete blood count with differential (CBC with diff), (2) retic count, (3) complete metabolic panel (CMP), (4) D-dimer, and (5) lactate dehydrogenase (LDH). A blood smear should be reviewed for evidence of schistocytes. Additional
laboratory studies may be necessary depending on the patient’s clinical status.

(d) **Lab Considerations**

Due to the mechanism of action of this medication, all activated partial thromboplastin time (aPTT)-based clotting assays, one-stage factor VIII and IX activity assays, and clotting-based inhibitor assays will appear to be normal and therefore are not useful in monitoring the patient’s disease process. Chromogenic-based assays which include chromogenic-based Bethesda assays and chromogenic factor VIII assays using bovine or human-derived reagents, prothrombin (PT)-based clotting assays, thrombin time, ELISA based assays, and genetic tests of clotting factors including factor V Leiden and prothrombin gene mutations are not affected by this medication. Due to the long half-life of the medication, these lab effects will remain in the plasma up to 6 months following the last dose of the medication, although at much reduced levels. The full effect of Hemlibra is noted after 4 weekly loading doses in all age groups.

(e) **Bleeding Treatment Recommendations on Hemlibra**

For a mild bleed, (e.g., mouth, soft tissue, or early joint bleed) observation alone is most likely the only treatment required. Additional treatment medications should not be given unless ordered through a hemophilia treatment center provider.

If the patient has a head, abdominal, or joint bleed, or other severe injury while on Hemlibra, treatment with factor VIII for factor levels of 80-100% (non-inhibitor patient) or recombinant factor VIIIa (Novoseven) at a dose of ~90 mcg/kg (inhibitor patient) should be administered under direct consultation with a hemophilia treatment center provider. In clinical trials, 1-2 doses of factor VIII (non-inhibitor patient) or Novoseven (inhibitor patient) is all that is usually needed to control bleeding. In many situations a single dose is all that is warranted. In some cases, more doses and close observation following a bleeding event for resolution may be required. This treatment should be considered before obtaining radiological studies, such as X-rays or CT scans when there is clinical evidence of a bleed, otherwise it is reasonable to wait for results based on clinical symptoms. **Patients and caregivers should not treat with Novoseven after an injury in anticipation of a bleed as one would have done prior to starting Hemlibra.**

For mucosal bleeding (mouth, nose, or gastrointestinal), an antifibrinolytic (i.e. aminocaproic acid or tranexamic acid) may be considered after discussion with a hemophilia treatment center provider.

(f) **Precautions and Warnings**

FEIBA should NOT BE GIVEN to any patient receiving Hemlibra unless directly ordered by a hemophilia treatment center provider and no sooner than 1 hour from delivery of Hemlibra due to risk of life-threatening thromboembolism or TMA. Thrombotic events occurred with cumulative amounts of FEIBA >100 units/kg for >24 hours in patients on Hemlibra. In certain situations, a reduced dose of FEIBA at a single dose of 10-15 units/kg may be given, but only under the consultation of a
3. **Cryoprecipitate**

With the availability of several virally-inactivated/virally-depleted factor VIII products and because cryoprecipitate has not undergone viral attenuation, **cryoprecipitate is NOT recommended for treatment of hemophilia A and should not be used routinely in the United States**. However, in an emergent situation and if factor VIII is not available, cryoprecipitate can be used. The average factor VIII content per bag of Cryo is 60-100 units. Transfusion dosing is 1 bag per 5-10 kilogram of body weight.

4. **DDAVP**

DDAVP, a synthetic vasopressin analogue and the intra-nasal formulation of DDAVP (Stimate™) are useful in the treatment of persons with mild hemophilia A who have a 6% or greater factor VIII level and who have been shown through **pre-testing** to be responsive to its administration. Rarely patients with moderate hemophilia A may have benefit from DDAVP.

DDAVP releases stored factor VIII into the circulation and increases the factor VIII level in patients with mild hemophilia A. This increased factor VIII level is often sufficient to provide hemostasis for minor bleeding episodes. The advantage of this product is that it reduces or avoids the exposure to blood and factor VIII products. Repetitive daily use will lead to diminished response called tachyphylaxis and should be limited to a maximum of 3 days with at least 24 hours between doses. Prior to therapeutic use, DDAVP should be evaluated as follows: measure the factor level pre-infusion; infuse DDAVP (0.3 micrograms per kilogram of body weight diluted in 30-50 mL of normal saline, up to a maximum total dose of 30 micrograms) slowly, over a 15–30-minute period; measure the factor VIII level 60 minutes and between 180–240 minutes post-infusion.

Stimate™, an intra-nasal preparation of DDAVP, is fifteen times more concentrated than the standard intra-nasal DDAVP used for treating diabetes insipidus and enuresis. RX: one spray in a single nostril (1 spray total) for children old enough to sniff on-command and under 50 kg, and one spray in each nostril (2 sprays total) for patients weighing over 50 kg. Because of marked variability in response to intra-nasal Stimate™, all patients should be tested before therapeutic use. As with IV DDAVP, repetitive use leads to a diminished response (i.e. tachyphylaxis). Accordingly, Stimate™ use should be limited to once every 24-48 hours and typically no more than 3 doses are needed.

It should be noted that in July 2020, the makers of Stimate™ issued an urgent voluntary recall of this medication as a result of testing that revealed a higher concentration and thus a higher potency of the medication than the label. Due to concerns for potential increases in side effects with administration of higher concentrations of desmopressin on vials dating back to 2018, all Stimate™ vials were recalled and are not currently available for use. Restoration of Stimate™ stocks for patient use remains unclear. An estimated time frame for the return of Stimate™ has been reported for some time between 2022 – 2024. As an alternative during the recall, some institutions have utilized subcutaneous DDAVP. The subcutaneous formulation of DDAVP has been proposed to have similar responses and efficacy as IV DDAVP. Subcutaneous DDAVP is administered at a dose of 0.3 micrograms per kilogram of body weight (maximum total dose 20-30 micrograms). Vials for subcutaneous DDAVP are available...
as either a single dose ampule (4 microgram/mL) or a multi-dose vial (4 microgram/mL with total volume of 10 mL that expires 30 days after opening). For subcutaneous injection, up to 2 mL (8 microgram) can be administered per injection thus multiple injections may be required.

There is potential risk of hyponatremia as a result of the concomitant release of vasopressin, the anti-diuretic hormone (ADH) with DDAVP or Stimate™. Fluid restriction to 3/4 maintenance of isotonic fluids for 24 hours following each dose administered is important. When intravenous fluids are being administered in the setting of multiple doses of DDAVP or Stimate™, the serum sodium should be monitored. Salt containing beverages such as Gatorade® (G or G2) or Powerade® are recommended for intake during the period of fluid restriction and caffeine should be avoided. Additionally, patients should contact their healthcare providers if they have symptoms of severe headache, weakness, or vomiting. The risk of hyponatremia is greatest in children less than age 3 and <15 kg and thus administration of DDAVP or Stimate™ should be avoided in this group of patients.

5. **Antifibrinolytic Agents**

(a) Epsilon-aminocaproic acid (Amicar or EACA) is an antifibrinolytic agent that can be used along with factor VIII products, particularly for invasive dental work or for the treatment of mouth or nose bleeds. It is not recommended for treatment of renal or bladder-related bleeding due to the potential risk of clot formation. The dose is 50-100 milligrams/kg (max 6 grams) every 6-8 hours for five to ten days (maximum 30 grams per 24 hours). Liquid and intranasal preparations are available. A mouthwash (swish and spit) utilizing the IV formulation of Amicar can be prepared for topical administration.

(b) Tranexamic acid (Cyklokapron™, TECA, or TA) is another antifibrinolytic agent. The oral form (Lysteda™) is approved for use in adolescent and adult females with heavy menstrual bleeding but can be used in similar situations as Amicar. Additionally, the IV form of TA can be used at a dose of 10 mg/kg/dose every 6-8 hours until healed. It is expected that this agent will also be effective in the treatment of other mucosal bleeds given its mechanisms of action. Lysteda™ is available in 650 mg tablets. Lysteda™ administration of 1300 mg three times a day for five days is recommended for the treatment of heavy menstrual bleeding. TA has been used as an alternative antifibrinolytic agent in individuals with adverse or allergic reactions to Amicar.

C. **Options Available for the Treatment of a Person with Factor IX Deficiency (Hemophilia B)**

1. **Factor IX**

As with factor VIII, there are recombinant standard half-life (SHL), recombinant extended half-life (EHL), and plasma-derived factor IX products available. Recombinant SHL factor IX products include BeneFIX, Rixubis, and Ixinity. Recombinant EHL factor IX products include Alprolix, Idelvion, and Rebinyn (not indicated for routine prophylaxis, but for on-demand or peri-operative use only). The plasma-derived factor IX products include AlphaNine. Plasma-derived factor IX product Mononine is no longer being produced and available supplies are expected to last only until mid-2021. Consult the product insert guide for specific instructions. Hemophilia of Georgia does not endorse a particular brand.
(a) These products are available for home therapy use through the Hemophilia of Georgia Pharmacy. Products are shipped directly to the home. Social workers are available to help Georgia residents explore insurance options.

(b) Vials are available in varying dosages between 250 – 5000 units.

(c) Each plasma derived factor IX IU per kilogram of body weight infused intravenously will raise the plasma factor IX level approximately 1%. The half-life of SHL products is about 18 to 24 hours. Due to a decreased recovery of factor, BeneFIX requires approximately 20-50% more product to achieve the same peak factor IX level, though some children require higher amounts. Accordingly, 1.2 IU/kg of BeneFIX in adults and 1.5 units/kg in children will raise the factor IX level by approximately 1%. The EHL products have a half-life that varies between 66-93 hours (approximately 3-4 days) depending on the age group and the EHL product.

(d) The formula for calculating the dosage for factor IX is taking the patient’s weight in kilograms and multiplying by the factor level desired, which will indicate the number of factor units required.

Formula: \[\text{Target Factor Level (IU/dl)} - \text{Baseline Factor Level (IU/dl)} \times \text{wt in kg} \times \text{Factor Recovery (IU/dl per IU/kg)}\]

- The target minus the baseline factor IX level is equal to the desired change in factor level.

Example: For a 45 kg boy with severe hemophilia B who has a joint bleed for which a change in factor IX level of 40% from baseline is desired, use the following equation:

\[40 \times 45 \text{ kg} + 1 = 1800 \text{ units of factor IX.}\]

If BeneFIX is used, multiply by 1.5 (children) or 1.2 (adults).

Refer to the chart on page 25 for suggested factor level and dosage based on type of hemorrhage.

(e) Factor IX should be infused according to the prescribing information. Recombinant products typically can be infused over several minutes whereas plasma-derived products may require slower infusion rates.

(f) In patients where the factor IX inhibitor status is unknown or in question, determination of factor recovery in 15-30 minutes after infusion by measuring factor IX levels may be advisable. Unlike patients with factor VIII deficiency (hemophilia A) and inhibitors, patients with factor IX deficiency (hemophilia B) may present with an allergic reaction (such as facial swelling, tongue swelling, difficulty breathing, wheezing, rash, hives, nausea/vomiting, pruritus), anaphylaxis, or nephrotic syndrome at the onset of their inhibitor. Patients should be evaluated immediately by a medical provider if they experience any of these symptoms during or after infusion with factor IX.

(g) Recombinant activated factor VIIa (Novoseven) can be used for the treatment of bleeding in patients with inhibitors to factor IX. The standard dose is 90 mcg/kg given
IV every 4-6 hours until hemostasis is achieved or until treatment is thought to be ineffective. FEIBA (Factor VIII Inhibitor Bypassing Agent) contains activated factors II, VII, IX, and X, thus it is contraindicated in patients with hemophilia B and inhibitors.

(h) Continuous infusion of purified factor IX is rarely indicated due to the longer half-life of factor IX products. If indicated, continuous infusion of factor IX should be supervised by an experienced hematologist utilizing similar guidelines as given for factor VIII other than dosing (start with a 100% bolus correction of factor IX at 100-140 units/kg and then start a continuous infusion of 6-8 factor IX units/kilogram/hr).

2. **Fresh Frozen Plasma (FFP)**

Fresh frozen plasma should not be used for these patients unless faced with a life-threatening emergency and only if factor IX products are not available. However, factor IX levels above 15-20% are difficult to achieve. A starting transfusion of 15-20 ml/kg FFP (1-2 units in adults) is an acceptable dose.

3. **Antifibrinolytic Agents**

Antifibrinolytic agents, either as primary or adjunctive therapy, are recommended for treating patients with factor IX deficiency who are treated with plasma or recombinant derived factor IX products. Treatment is similar to previous suggestions for use in factor VIII deficient patients (see page 10, section B.5).

D. **Specific Hemorrhages**

1. **Joint Hemorrhage**

(a) First give the patient the appropriate dose of factor and then evaluate. X-rays are indicated in the setting of trauma where injury to the bone is suspected.

(b) Raise the factor level to at least 40-50% with first symptoms of a joint bleed or after trauma. (Refer to previous explanations about calculations.) Typically, many HTCs recommend raising the level to 100% with first symptoms of joint bleeding. For a more significant joint hemorrhage, a bleed in a target joint (defined as three bleeds into a single joint during the previous 6 months) or joint bleeding in children, always raise the level to 80-100% and call one of the hemophilia treatment centers.

(c) A second infusion to raise the factor level to 40-50% in 24 hours (hemophilia A) or in 48 hours (hemophilia B) and a third infusion to 40–50% (hemophilia A) in 72 hours are recommended in children and may be needed in adults if symptoms persist (i.e., if swelling and/or pain is not significantly improved).

(d) The so-called “target joint bleeding” protocol for severe and moderate hemophilia A in which the patient receives 80-100% correction on the day of the bleed (day 1), and 40-50% correction on day 2 and 4 post-bleed, can be beneficial for many patients including children and those with target joints. For severe hemophilia B, the “target joint bleeding” protocol consists of 80-100% correction on the day of the bleed (day 1) and 50% correction on day 3 post-bleed. Utilization to be determined by the HTC.
13

Physician's Hemophilia Hotline
1-888-549-6493

(e) Immobilize the joint as soon as possible until pain subsides. A cryocuff is most helpful.

(f) Adjunctive care: ice applied to area of bleeding, temporary rest, and elevation.

(g) Seek consultation at a hemophilia treatment center if symptoms persist beyond three days or if a fracture is suspected.

(h) Pain control: aspirin-free medication. (See Appendix, page 26.)

2. **Muscle Hemorrhage**

(a) First give the patient the appropriate dose of factor and then evaluate. Look particularly for signs of neurovascular compromise (i.e., compartment syndrome).

(b) Raise the factor level to 40-50% with first symptoms or after trauma. More severe muscle hemorrhages require higher dosing of factor to a level of 80-100% as described above for treatment of joint bleeding. (Refer to previous explanations on page 6 or 11 about calculations for hemophilia A and B, respectively.)

(c) A second infusion with factor to raise the factor level to 40-50% is often required within 24 hours. Continue to monitor for neurovascular compromise.

3. **Iliopsoas Hemorrhage**

(a) This is a form of muscle hemorrhage with a unique presentation. This type of bleed often presents as an acute abdomen or as hip pain. Signs may include pain in the lower abdomen, groin, and/or lower back, and pain on extension, but not on rotation, of the hip joint. There may be paresthesia in the medial aspect of the thigh or other signs of femoral nerve compression. This is considered a serious bleed as significant "occult" blood loss may occur leading to anemia, possible compartment syndrome and femoral nerve damage.

(b) Immediately raise the factor level to 80-100%. Maintain factor levels above 50% for both hemophilia A and B for 48 to 96 hours, as symptoms dictate. Often, prolonged periods of factor use are needed as well as consideration of continuous infusion of factor.

(c) An imaging study, e.g., CT scan or ultrasound, will confirm the diagnosis of an iliopsoas hemorrhage and help differentiate from acute appendicitis, for which this condition is often mistaken.

(d) Hospitalize for observation. Treat anemia as needed.

(e) Limit activity until pain resolves. Physical therapy is helpful to restore full range of motion. Refer to a hemophilia treatment center.

4. **Central Nervous System (CNS) Hemorrhage/Head Trauma**
(a) Treat all post-traumatic head injuries and significant headaches as a head bleed. Raise factor level immediately to 80-100%. **Do not wait for further symptoms to develop or for laboratory or radiological evaluation.**

(b) **This is a true medical emergency. Treat presumptively before evaluating.** Immediately raise factor level to 80-100% when CNS symptoms or significant trauma occur. If a hemorrhage has occurred, maintain at least an 80% factor level until the hemorrhage has improved (usually two weeks) with an objective head imaging study performed. Total treatment typically lasts 4 weeks with a lower factor goal of >25-50%. Initiation of a continuous infusion of factor should be considered. Consult the hemophilia treatment center for further recommendations once the patient has been stabilized. These patients will often go on long-term prophylaxis to maintain a goal factor trough >1%.

(c) This requires immediate medical evaluation and hospitalization for observation. A head CT scan or MRI should be performed.

(d) In the case of suspected head trauma, first treat the patient with factor and then evaluate.

(e) Severe headache may also be a manifestation of HIV-related opportunistic infection. (See section IV, C, HIV Issues, page 22-23.)

5. **Throat and Neck Hemorrhage and Severe Tonsillitis**

(a) **This is a true medical emergency. Treat presumptively before evaluating.** Immediately raise factor level to 80-100% when symptoms or significant trauma occur. Maintain at least a 50% factor level for one to two weeks until the hemorrhage resolves. Consult the hemophilia treatment center for further recommendations once the patient has been stabilized.

(b) Trauma or symptoms of hemorrhage usually require hospitalization or follow-up by a hematologist and an otolaryngologist. A CT scan or MRI should be performed.

(c) To prevent hemorrhage with severe tonsillitis, treatment with factor may be indicated in addition to culture and treatment with antibiotics.

6. **Acute Gastrointestinal Hemorrhage**

(a) First, give the patient the appropriate dose of factor and then evaluate.

(b) Immediately raise the factor level to 80-100%. Maintain at least a 50% factor level until the etiology is defined.

(c) Medical evaluation and possibly hospitalization are required for signs of gastrointestinal (GI) bleeding and/or acute abdomen.

(d) Treat anemia or shock as needed.
(e) Treat the origin of hemorrhage as indicated.

(f) Aminocaproic acid or tranexamic acid may be used as adjunctive therapy as long as the possibility of concomitant renal bleeding has been eliminated. Consult a hemophilia treatment center for recommendations.

7. **Acute Abdominal Hemorrhage**

(a) Acute abdominal hemorrhage can mimic a number of infectious conditions and appropriate radiological studies are often necessary. Iliopsoas hemorrhage should be ruled out. (See section II, D, 3, Iliopsoas Hemorrhage, sections (a) and (b), page 13).

(b) **Immediately** raise the factor level to 80-100%. Maintain at least a 50% factor level until the etiology can be defined. Consult the hemophilia treatment center for recommendations.

8. **Ophthalmic Trauma or Hemorrhage**

(a) First give the patient the appropriate dose of factor and then evaluate.

(b) **Immediately** raise the factor level to 80-100%. Maintain a factor level of at least 50%.

(c) An evaluation by an ophthalmologist and a hematologist is required with symptoms or signs of trauma or hemorrhage to help prevent vision loss.

9. **Renal Hemorrhage**

(a) Avoid use of antifibrinolytic agents for renal bleeding unless directed by a hemophilia treatment specialist. Lower urinary tract bleeding may respond to antifibrinolytic therapy. Decision on use of antifibrinolytics in this situation should include a discussion with a Urologist and Hematologist.

(b) Painless hematuria should be treated with bed rest and vigorous hydration (1-1/2 times maintenance) for 48 hours.

(c) If there is pain or gross hematuria, give factor to raise the level to 50%.

(d) Evaluate if hematuria (gross or microscopic) persists or if there are repeated episodes.

10. **Oral Hemorrhage**

(a) Bleeding may be controlled with the use of aminocaproic acid or tranexamic acid alone, or with the use of factor and either aminocaproic acid or tranexamic acid, if bleeding is prolonged, significant, or difficult to control. Treatment of a frenulum bleed in infants should be aggressive with factor replacement to at least 50% for at least 3 days.
(b) Evaluate and treat for anemia as indicated.

(c) The application of topical agents such as Avitene or Thrombin on the bleeding mucous membrane may be effective. Topical formulations of Amicar may also be effective. Ice in the form of popsicles may also be effective, but red ones should be avoided to evaluate for further bleeding. A soft, cold diet for 24 hours is recommended.

(d) Consult a hematologist, a dentist or an otolaryngologist as indicated.

(e) A custom fit mouthpiece might be helpful to provide local compression.

11. **Epistaxis**

(a) Factor replacement therapy is usually not required because the formation of a platelet plug often is adequate.

(b) Have the patient place his head forward to avoid swallowing blood and have him gently blow out weak clots. Apply firm pressure to the fleshy part of the nose for at least 10-20 minutes without turning loose.

(c) Treatment of allergy symptoms that may trigger or increase the frequency of epistaxis with antihistamines or intranasal corticosteroids may be beneficial.

(d) Watch for anemia if bleeding is prolonged or occurs frequently.

(e) ENT consultation may be indicated.

(f) The use of aminocaproic or tranexamic acid may be helpful. The intranasal formulation of aminocaproic acid or tranexamic acid is particularly helpful for nosebleeds and can be administered as 1 spray per nostril every 4-6 hours as needed. The administration of different formulations of aminocaproic acid or tranexamic acid at the same time should be avoided.

(g) Use of normal saline solution or gel (Ayr™/Little Noses®) is extremely useful for prevention of epistaxis.

(h) Nose clips might be helpful to keep pressure applied for 10-20 minutes.

(i) In cases of prolonged bleeding not improved by antifibrinolytics or a severe nosebleed resulting in significant blood loss or worsening anemia, administration of factor to at least 50% should be considered.

12. **Soft Tissue Hemorrhage**

(a) Most superficial soft tissue bleeding does not require factor replacement therapy. The application of firm pressure and cool compress may be helpful.
(b) Evaluate for severity and possible muscular or neurovascular involvement. Rule out the possibility of trauma to spaces containing vital organs, such as the head or abdomen. Open compartmental hemorrhage such as in the retropharyngeal, mediastinal, or retroperitoneal space, scrotum, buttocks or thighs can result in extensive blood loss. If this is suspected, treat with factor to 80-100% immediately.

(c) A young, active child with hemophilia commonly has numerous bruises. Parents are sometimes **wrongfully** accused of child abuse. Providing early education on hemophilia to daycare providers or school officials may be beneficial.

13. **Lacerations and Abrasions**

(a) Superficial lacerations can be treated by cleaning the wound followed by application of pressure and steri-strips.

(b) Abrasions require cleaning and pressure.

(c) Deep lacerations require raising the factor level to 50%, then suturing. Removal of sutures usually requires another infusion of factor.

E. **von Willebrand Disease**

von Willebrand Disease (VWD), is inherited on an autosomal basis and thus affects females and males equally. Because of reproductive tract bleeding the rates of diagnosis are much higher in adolescent girls and women. The disease is due to a reduction or abnormality of a glycoprotein (called von Willebrand factor or VWF) in the blood that is necessary for adhesion of the platelet to the vessel wall. Because this protein also serves as the carrier protein and stabilizer of factor VIII, factor VIII activity in the blood is sometimes decreased in proportion to the reduction in measurable von Willebrand factor.

Several types of VWD have been identified. Patients with Type 1 VWD have both the most common and usually the mildest form of the disorder. They have reduced levels of VWF, but its structure and function appear to be normal. Patients with Type 2 VWD have varying levels of VWF, but the protein does not function properly, as manifested by a lower functional activity most commonly measured as ristocetin cofactor activity or GPIbM activity. There are several variants of Type 2; the most important to distinguish is Type 2B VWD because of possible complications if DDAVP is utilized (see below). Type 3 VWD patients are severely affected because they have an absence of VWF and concomitant reduction in circulating factor VIII—these patients may behave like those with moderate hemophilia A.

Symptomatic individuals with VWD will usually present with mucosal bleeding (e.g., epistaxis, oral, GI or GU bleeding, or easy bruising). Heavy menstrual bleeding is a common problem for women with this bleeding disorder.

The mainstays of treatment for most types of VWD are DDAVP and factor VIII concentrates rich in VWF. Bleeding patients with Type 1 VWD can generally treat with antifibrinolytics and DDAVP (see page 9-10); some patients with Type 2M may also respond to its use.

DDAVP may be given intranasally, subcutaneously or intravenously and causes release of VWF from storage sites. It is effective for 3 days before tachyphylaxis occurs (i.e. decreased response to the medication over time). Patients should be tested to ensure a response before it is prescribed for treatment of bleeding symptoms.
It is important to note that there is a risk of hyponatremia with DDAVP administration and fluid intake should be carefully monitored. If DDAVP is not available, a documented inadequate clinical response, or there is severe or life-threatening bleeding, the treatment of choice is any VWF rich concentrate (see below). Those with Types 2B, 2N, or 3 disease who are bleeding should NOT be treated with DDAVP. Type 2B patients may develop platelet clumps with resultant thrombocytopenia when treated with DDAVP, and Type 3 patients will not increase their VWF in response to DDAVP. The appropriate treatment for patients with these types of VWD is a factor VIII product rich in VWF or a recombinant VWF product. The most widely available VWF-rich factor VIII product is Humate-P. It is often administered at a dose of 30-50 VWF ristocetin cofactor (RCoF) units/kg for bleeding episodes depending on the patient’s baseline VWF ristocetin cofactor activity level. Other factor VIII products that contain substantial amounts of VWF are Alphanate, Wilate, and Koate DVI. All of these are made from plasma screened for HIV and hepatitis viruses and are treated to inactivate viruses that might escape detection. All of these products with the exception of Koate DVI are licensed for the treatment of VWD and the lyophilized bottles containing these products are labeled in both ristocetin cofactor units and factor VIII units. Highly purified factor VIII products—monoclonal and recombinant—cannot be used to treat VWD because they lack VWF.

Vonvendi is the only recombinant VWF product currently available. It was FDA approved in 2015 for patients >18 years with VWD for the on-demand and peri-operative treatment of bleeds. It can be infused at 40-50 units/kg for minor bleeds and 50-80 units/kg for major bleeds. It is important to note that if a patient with VWD has a baseline factor VIII activity level less than 40% or if the level is unknown, they will need to infuse a recombinant, non-VWF containing factor VIII product within 10 minutes of the first VonVendi administration for a bleeding episode. This is due to a delayed rise in the plasma factor VIII level after VonVendi is administered. Subsequent doses of factor VIII may not be necessary with repeat doses of VonVendi depending on plasma levels 6-8 hours after infusion.

Cryoprecipitate, which is screened for viruses but not treated to inactivate them, is also rich in VWF. Because it is likely to be less safe than the virally attenuated products, its use is NOT recommended in the United States unless a concentrate is not available.

For mucosal bleeding, treatment with antifibrinolytics aminocaproic acid or tranexamic acid can also help. For women with heavy menstrual bleeding, hormonal therapy with various forms of estrogen-containing or progesterone only hormonal therapies may help, as well as DDAVP and antifibrinolytic agents such as Lysteda™.

Given the risk of bleeding in all VWD patients with surgery, a bleeding treatment plan should be established with the help of a hematologist specializing in bleeding disorders prior to the procedure taking place. All patients should wear a medic alert and have an emergency treatment letter available.

III. OTHER MANAGEMENT ISSUES

A. Dental

1. Routine examinations and cleanings generally can be performed without raising the factor level. Adequate coverage (i.e., factor or antifibrinolytic therapy) should be given prior to and possibly after the dental appointment in those patients who need deep cleaning or have heavy plaque and/or calculus accumulation where bleeding would be induced with scaling. Factor should always be given prior to dental procedures where local anesthesia via a nerve block is
given. In mild and some moderate hemophilia patients, infusion of factor may not be necessary prior to restorative work if only local infiltration of anesthesia is going to be used.

2. Raise the factor level to at least 50% prior to giving a mandibular block. Local anesthesia is not contraindicated for hemophilia patients. Nitrous oxide and/or IV analgesia may be used in addition to local anesthesia.

3. Dental extractions require an infusion of factor that raises the level to 80-100%. Antifibrinolytic products should be used concomitantly with factor infusion or DDAVP/Stimate™. The dose for aminocaproic acid started prior to the procedure, is 50-100 milligrams/kg every 6-8 hours, for up to 7-10 days (maximum 30 grams per 24 hours). The dose for tranexamic acid is 10 milligrams/kg orally every 8 hours for up to 7-10 days. Unless contraindicated, we generally recommend the use of antifibrinolytic agents until the sutures dissolve and the site is well healed. Factor infusions after the extractions may also be necessary.

4. When primary teeth are exfoliating, bleeding may occur. Pressure and ice should be used as a first attempt to control bleeding. If this is ineffective, aminocaproic acid can be used. In rare instances, factor may need to be administered. For patients with a history of prolonged bleeding, it may be appropriate for the dentist to extract the tooth with proper factor infusion.

5. Extensive procedures may require hospitalization for proper dental/medical management; for example, procedures requiring sutures, multiple extractions, etc.

6. The position of the third molars (wisdom teeth) should be evaluated during teenage years. Early extraction should be considered to prevent complications or a more extensive surgical approach when older. We usually recommend infusion of factor for several days after wisdom teeth extractions in addition to antifibrinolytic therapy with aminocaproic acid or tranexamic acid.

7. Avitene and/or gel foam pre-soaked in topical thrombin solution can be used as a hemostatic agent in the extraction site or on oozing gingiva. When possible, primary closure is desirable.

8. The above recommendations are general guidelines. Each patient should be evaluated on an individual basis according to the severity of his condition and dentist or oral maxillofacial surgeon input. A consultation with a hematologist familiar with the patient is recommended.

9. Patients with inhibitors require close collaboration with a hemophilia treatment center hematologist for an individualized bleeding plan.

B. Surgery

1. Management of the surgical patient is best undertaken at a hemophilia treatment center. The institution undertaking such procedures must be capable of performing a factor inhibitor screen prior to the scheduled surgery and measurement of serial factor levels during the surgical procedure.

2. Operative and invasive procedures can be performed once the coagulation defect is corrected by infusion with factor. Consultation with a hematologist familiar with hemophilia is necessary.
3. The patient’s individual response to the replacement material should be documented prior to surgery. (If the patient does not respond adequately, the presence of an inhibitor should be considered. See section IV, A, Factor Inhibitor, page 21.)

4. Immediately prior to the procedure, raise the calculated factor level to 80-100%; maintain at least a 50% level for one to two weeks, depending on the type of surgery. Continuous infusion of factor may be preferable for the management of surgical patients. Factor levels should be monitored at least daily during continuous infusion.

5. Maintain an appropriate factor level for 5-7 days for minor surgery; 10-14 days for major surgery; and prophylaxis 3-4 times a week for up to 6 weeks for orthopedic procedures during rehabilitation.

C. Invasive Procedures

Factor should be infused before invasive diagnostic procedures such as lumbar puncture, arterial blood gas determination, bronchoscopy, liver biopsy, colonoscopy or endoscopy with brushings or biopsy.

D. Immunizations

1. Many vaccinations can be given subcutaneously, which is the recommended route of administration by the World Federation of Hemophilia (WFH) for immunizing persons with moderate to severe hemophilia. There is good evidence for the effectiveness of both hepatitis A and B vaccinations as well as Diphtheria, Tetanus and acellular Pertussis given subcutaneously in persons with hemophilia. For other vaccinations, refer to the prescribing information for the appropriateness of subcutaneous administration. If a vaccination is to be given intramuscularly, some patients may need to receive factor replacement prior to the injection. Application of a cool compress to the site after vaccination may also be helpful. The smallest size needle (25 or 27 gauge) should be used. An ice pack and firm pressure without rubbing should be applied for 5 minutes after the injection. Subcutaneous injections can be given without factor replacement therapy even in patients with severe hemophilia. Immunizations should be limited to 2 vaccines per visit (1 vaccine per extremity) in young children. In children with mild hemophilia or most cases of VWD, no factor replacement is needed. Alternatively, in cases of moderate to severe hemophilia on factor prophylaxis one should time the dose of prophylaxis to be the same morning of the vaccination to avoid an intramuscular hematoma.

2. Live viral vaccines should not be given to immunocompromised patients without consultation with an ID specialist.

3. Persons with HIV should be given pneumococcal and annual influenza vaccines.

4. The hepatitis A and hepatitis B vaccine series should be given to all newly diagnosed patients and to those indicating no exposure to either hepatitis A or hepatitis B virus. Family members involved in factor replacement therapy in the home who test negative should also receive the series. Vaccine can be given subcutaneously in the thigh or over the deltoid area (the deltoid is preferable). Antibody to hepatitis B virus should be determined following the full immunization schedule to ensure immunity.
COVID-19 Vaccination: In 2020, the World Health Organization declared a pandemic as a result of the SARS-CoV-2 virus (COVID-19). Individuals with a bleeding disorder have the same risk of contracting COVID-19 as the general population. Vaccination against COVID-19 is NOT contraindicated in individuals with a bleeding disorder. There is currently no specific preference for a type of vaccine in bleeding disorder patients. Studies evaluating the efficacy and safety of COVID-19 vaccines have only evaluated these outcomes in COVID-19 vaccines administered via the intramuscular route. Therefore, the COVID-19 vaccine should be administered intramuscularly using the smallest gauge needle available (25-27 gauge) in individuals with a bleeding disorder. Pressure should be applied to the injection site for at least 10 minutes and a cool compress/ice pack applied for at least 5 minutes. If the patient receives clotting factor prophylaxis, vaccination should occur on a prophylaxis day. Individuals with hemophilia A on emicizumab can receive the vaccine at any time without an additional dose of clotting factor.

6. The National Hemophilia Foundation Medical and Scientific Advisory Council (MASAC) and WFH evaluate the safety, efficacy, and optimal protocols for vaccine administration of existing and emerging vaccines on an ongoing basis. Any changes in these recommendations will be promptly updated.

E. Sports and Hemophilia

1. Sports activities should be encouraged to promote muscle strengthening and increased self-esteem. Choice of sports should reflect an individual’s preference, physical ability and physical condition.

2. Low impact activities such as swimming and golf should be encouraged. High contact sports such as football, wrestling and hockey are not advised. The patient should consult with a physician before engaging in sports activities to discuss appropriateness, protective gear, and prophylaxis prior to the activity. The “Playing It Safe - Bleeding Disorders, Sports and Exercise” handbook produced by the National Hemophilia Foundation is an excellent resource for providers, patients, and families on physical activity in individuals with a bleeding disorder. This resource is available at: https://www.hemophilia.org/sites/default/files/document/files/Playing-It-Safe.pdf

IV. COMPLICATIONS OF HEMOPHILIA

A. Factor Inhibitor: Neutralizing IgG Antibodies to Factors VIII and IX

An inhibitor should be suspected if the patient does not respond to the usual dose of factor. The previous guidelines in these protocols do not apply to patients with inhibitors. Management of this difficult problem must be coordinated with the expertise of a hematologist who specializes in bleeding disorders.

B. Synovitis

1. The clinical findings are a distended (but not tense or painful) joint, usually involving the knee, ankle or elbow.
2. Following treatment of any suspected bleeding, treatment is directed at decreasing inflammation. Selective Cox-2 inhibitor non-steroidals such as Celebrex and Mobic have less potential bleeding as they do not inhibit platelet function and could be considered in this setting. Use of Celebrex should be limited to the lowest effective dose. Caution should be used when Celebrex is used in the setting of hepatic impairment. Doses should be reduced by 50% in patients with Child-Pugh class B hepatic impairment and use is not recommended in the setting of severe hepatic dysfunction. Do not use aspirin-containing medications. Refer the patient for multidisciplinary evaluation at a hemophilia treatment center.

3. This problem is difficult to manage and is best handled by a team approach, specifically by the hematologist, orthopedist, and physical therapist at the hemophilia treatment center.

C. HIV Issues

1. Many persons with hemophilia who were treated with plasma-derived factor prior to 1985 are HIV seropositive. Most persons with hemophilia are aware of their serostatus, although some are reticent to discuss their HIV infection. Consequently, health care providers should be aware of the probability of HIV infection in a person with hemophilia born before 1985. A significant percent of HIV-infected hemophiliacs have survived more than two decades with this bloodborne infection and are clinically doing very well. Although the manifestations of the opportunistic infections seen with HIV infection are protean and beyond the scope of this document, clues to the presence of progressive HIV infection and common presenting problems of persons with acute or advanced HIV infection include:
   - unexplained fever
   - anorexia/weight loss/wasting
   - pharyngitis or odynophagia
   - significant periodontal disease
   - oral candidiasis
   - headaches (which may be a manifestation of meningitis)
   - recurrent sinusitis
   - seborrheic dermatitis or other chronic dermatoses
   - history or presence of herpes zoster (shingles)
   - pneumonia
   - chronic diarrhea
   - lymphadenopathy

2. Causes of pneumonia in this setting include *Pneumocystis jiroveci* (PJP), formerly known as *Pneumocystis carinii* (PCP), common bacterial pathogens, mycobacteria, fungi and a variety of uncommon organisms. If pulmonary tuberculosis is suspected, appropriate isolation precautions should be instituted.

3. Thrombocytopenia can be a complication of HIV infection and can cause bleeding independent of the bleeding disorder seen in patients with hemophilia.

4. Plasma-derived factors available since 1985 and the new recombinant products have eliminated the risk of HIV infection. Therefore, patients born after 1985 are at no increased risk for HIV infection unless there are other risk factors. Routine serologic screening of source plasma, viral inactivation procedures, and the development of recombinant products
are responsible for this important advance.

5. For the rare person with hemophilia whose HIV serostatus is unknown, voluntary, confidential testing and pre- and post-test counseling are available through the comprehensive hemophilia centers. HIV risk reduction counseling is also available.

6. If a health care worker sustains a significant exposure to blood or body fluids from a patient with hemophilia, the potential for transmission of bloodborne pathogens should be considered. In addition to having HIV infection, many persons with hemophilia also have chronic hepatitis C infection and a few have chronic hepatitis B.

D. Hepatitis C

1. Most persons with hemophilia who received clotting factor before 1990 acquired hepatitis C infection. Almost all patients with hemophilia with HIV infection have hepatitis C co-infection. Hepatitis C infection causes chronic hepatitis in >80% of cases and can lead to cirrhosis and hepatocellular carcinoma (liver cancer).

2. Hepatitis C is primarily spread through blood/percutaneous transmission. Sexual transmission of hepatitis C is uncommon in heterosexual couples, however there is higher risk of sexual transmission in men who have sex with men (MSM). Regardless, it is now recommended by the American Association for the Study of Liver Diseases (AASLD) that all adults be screened for Hepatitis C and this recommendation should be conveyed to patients in order to have their partners tested.

3. Alcohol consumption can accelerate the progression of hepatitis C liver injury and its use should be discouraged.

4. Persons with chronic hepatitis C are more susceptible to the hepatotoxic effects of other drugs. Acetaminophen is not contraindicated in chronic hepatitis C, although those with cirrhosis should use with caution and should limit acetaminophen dosage to <2 gm/day.

5. Nonalcoholic fatty liver disease (NAFLD) is also a risk factor for fibrosis progression in patients with hepatitis C. Patients who are overweight or obese should be counseled on diet, exercise and medical therapies to reduce weight and improve insulin resistance.

6. Persons with chronic hepatitis C can have a more severe illness should they contract hepatitis A or B; consequently, persons with hepatitis C infection should be screened for hepatitis A and B and offered vaccine should they be non-immune.

7. Liver biopsy is no longer routinely recommended for staging severity of hepatitis C infection and fibrosis. There are now non-invasive measures including laboratory modalities such as aspartate aminotransferase-to-platelet ratio (APRI), Fibrosure, Fibrotest, as well as transient elastography (Fibroscan). Liver biopsy can be considered when two of the non-invasive tests are discordant or there is need to evaluate for additional causes of liver disease.

Most patients with hemophilia can, with clotting factor infusion, safely undergo liver biopsy to help stage hepatitis C. Liver biopsies should be performed at a referral center with expertise in managing clotting factor infusion.
8. Although treatment for hepatitis C previously had many side effects, newer treatment regimens using combinations of directly acting antiviral agents (DAAs) have emerged with improved side effect profiles, shorter required duration of treatment and improved efficacy (up to 95% rates of sustained virologic response). Particularly in patients with bleeding disorders, these newer non-interferon DDA agents have proven to be highly effective and safe. Treatment should be coordinated with a hepatitis C specialist.

There are now multiple recommended regimens for treatment naïve patients that are beyond the scope of this document. Regimens vary based on HCV genotype, HCV viral load and the presence or absence of cirrhosis. Recommendations change rapidly as new agents are approved. Refer to published AASLD/guidelines for further information.

Given improved efficacy of the new DAAs, patients who failed prior HCV treatment should be offered re-treatment. Regimens vary based on HCV genotype, prior response to therapy, and presence of cirrhosis. Refer to published AASLD/IDSA guidelines for further information.

Hepatitis C patients with cirrhosis should be screened for liver cancer and esophageal varices according to published guidelines. Determining the presence of cirrhosis should be made using a combination of clinical judgment, imaging, and non-invasive fibrosis staging.

E. Allergic Reactions to Factor Replacement Products

1. Allergic reactions to factor replacement products are rare but have been reported. Specifically, an allergic reaction is a potential, though uncommon, side effect of factor VIII or factor IX products modified by pegylation to extend factor half-life.

2. Patients with an allergic reaction after factor infusion should seek immediate medical attention. A hemophilia treatment center provider should be notified if there are concerns for an allergic reaction due to factor administration. Antihistamines such as Benadryl (and on rare occasions, steroids) may be used to treat acute symptoms.

3. It is important to realize that anaphylaxis can be associated with inhibitor development in patients with hemophilia B (see section C.1, factor IX, page 10-11).
### DESIRED PLASMA FACTOR LEVEL AND DOSAGE FOR BOLUS INFUSIONS (RESOURCE-RICH COUNTRIES)

<table>
<thead>
<tr>
<th>TYPE OF HEMORRHAGE</th>
<th>HEMOPHILIA A (VIII)</th>
<th></th>
<th>HEMOPHILIA B (IX)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Desired Level</td>
<td>Dose (IU/kg)</td>
<td>Desired Level</td>
<td>Dose* (IU/kg)</td>
</tr>
<tr>
<td>Joint</td>
<td>Adults</td>
<td>40-50%</td>
<td>20-25</td>
<td>40-50%</td>
</tr>
<tr>
<td></td>
<td>Children</td>
<td>80-100%</td>
<td>40-50</td>
<td>80-100%</td>
</tr>
<tr>
<td>Muscle (except iliopsoas)</td>
<td></td>
<td>50%</td>
<td>25</td>
<td>50%</td>
</tr>
<tr>
<td>Iliopsoas</td>
<td>Initial</td>
<td>80-100%</td>
<td>40-50</td>
<td>80-100%</td>
</tr>
<tr>
<td></td>
<td>Maintenance</td>
<td>50%</td>
<td>25**</td>
<td>50%</td>
</tr>
<tr>
<td>CNS/Head</td>
<td>Initial</td>
<td>80-100%</td>
<td>40-50</td>
<td>80-100%</td>
</tr>
<tr>
<td></td>
<td>Maintenance</td>
<td>50%</td>
<td>25**</td>
<td>50%</td>
</tr>
<tr>
<td>Throat and Neck</td>
<td>Initial</td>
<td>80-100%</td>
<td>40-50</td>
<td>80-100%</td>
</tr>
<tr>
<td></td>
<td>Maintenance</td>
<td>50%</td>
<td>25**</td>
<td>50%</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Initial</td>
<td>80-100%</td>
<td>40-50</td>
<td>80-100%</td>
</tr>
<tr>
<td></td>
<td>Maintenance</td>
<td>50%</td>
<td>25**</td>
<td>50%</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>Initial</td>
<td>80-100%</td>
<td>40-50</td>
<td>80-100%</td>
</tr>
<tr>
<td></td>
<td>Maintenance</td>
<td>50%</td>
<td>25**</td>
<td>50%</td>
</tr>
<tr>
<td>Renal</td>
<td></td>
<td>50%</td>
<td>25</td>
<td>50%</td>
</tr>
<tr>
<td>Deep Laceration</td>
<td></td>
<td>50-100%</td>
<td>25-50</td>
<td>50-100%</td>
</tr>
<tr>
<td>Surgery</td>
<td>Initial</td>
<td>80-100%</td>
<td>40-50</td>
<td>80-100%</td>
</tr>
<tr>
<td></td>
<td>Maintenance</td>
<td>50%</td>
<td>25**</td>
<td>50%</td>
</tr>
</tbody>
</table>

* For recombinant Factor IX product BeneFIX, multiply x 1.2 – 1.5. In general, the younger the child the higher the correction factor with 1.2 appropriate for most.

** In general, maintenance doses for Hemophilia A are given every 12 hours. This may need to be modified according to the individual patient's half-life and the factor product.

*** In general, maintenance doses for Hemophilia B are given every 24 hours. This may need to be modified according to the individual patient's half-life and the factor product.

**NOTE:** In patients where the factor inhibitor status is unknown or is in question, determination of factor recovery 15-30 minutes after infusion by measuring factor levels may be advisable. For severe bleeds that are limb- or life-threatening, the trough level should be kept above 50%.
## COMMON PREPARATIONS CONTAINING ASPIRIN

| Acuprin 81 | Halfprin |
| Aggrenox Capsules | Helidac Therapy |
| Alka Seltzer (all preparations) | Kaopectate |
| Alka Seltzer w/Aspirin | Levacet |
| Alor | Lobac Capsules and Tablets |
| Anacin | Lortab ASA |
| Arthritis Pain Formula | Magnaprin |
| Ascripton | Magsal Tablets |
| Aspergum | Methocarbamol & Aspirin Tablets |
| Aspidrox | Methocarbamol w/ASA |
| Aspircaf | Midol |
| Aspir-Mox | Micrinin |
| Aspirtab | Miniprin |
| Aspir-trin | Minilabs |
| Axotal Tablets | Momentum |
| Azdone | Mono-Gesic Tablets |
| Bayer | Norgesic |
| Bayer Childrens | Norgesic Forte |
| B-C Cold-Sinus-Allergy Powder | Norwich Aspirin |
| B-C Powder | Orphengesic |
| B-C Tablets | Oxycodone w/Aspirin |
| Bufferin | Pamprin |
| Buffex | Panasal |
| Carisoprodol Compound | Pepto Bismal |
| Cosprin Tablets | Percodan |
| CVS Aspirin | Percodan Demi |
| Darvon Compound-65 | Ridiprin |
| Damason-P | Rite Aid Aspirin |
| DeWitt’s Pills | Robaxisal |
| Disalcid Capsules and Tablets | Roxinprin |
| Doans | Saelto |
| Dristan | Salflex Tablets |
| Easprin | Salsalate Tablets |
| Ecotrin | Sine-Off |
| Empirin | Sloprin |
| Endodan Tablets | Soma Compound |
| Entaprin | Soma Compound W/Codeine |
| Entercote | St. Joseph |
| Empirin w/Codeine | Stanback Analgesic |
| Equagesic | Supac |
| Excedrin | Synalgos DC |
| Excedrin Back and Body | Talwin Compound |
| Fasprin | Uni-Buff |
| Fiorinal | Uni-Tren |
| Fiorinal w/Codeine | Valomag |
| Fiorital with Codeine Capsules | Vanquish |
| Genacote | Walgreen’s Aspirin |
| Gennin-FC | YSP |
| Genprin | Zorprin |
| Goody’s | Power’s Hemophilia Hotline 1-888-549-6493

Because this is a partial list, **ALWAYS** check the ingredients in both prescription and over-the-counter medications for acetylsalicylic acid (A.S.A.).